Hims & Hers expanded its subscriber benefits bundle to ten partner brands. The update is not a direct revenue story yet; it is a retention, churn, and marketing-efficiency proof test.
Open HIMS Q1 met the revenue test and raised revenue guidance, but lower margins and reduced adjusted EBITDA guidance keep the thesis conditional.
Open Hims is using GLP-1 weight loss to expand the platform, but the quality test is retention and cash flow.
Open Hims & Hers opened a Canada generic semaglutide path and closed $402.5M of zero-coupon convertible debt. The update turns HIMS into a global expansion versus dilution proof test.
Open SEC filings, financial facts, source resources, and Goglides workspace context for Hims & Hers Health, Inc..
Open AI data centers need power and cooling before they need another software demo.
Open Revvity is trying to prove the post-spin model can protect margins while faster life-science competitors chase growth.
Open Rocket Lab is scaling space systems and launch operations, but the financial question is how much R&D the model can absorb.
Open Rocket Lab has launch credibility, but Neutron must prove it can move the company beyond small-launch economics.
Open SoFi is growing across lending, financial services, and technology, but credit risk decides how durable the growth is.
Open Small modular reactors sound like a data-center power answer, but NuScale still has to prove commercialization.
Open AI-server demand is large, but the liquidity story is about cash, working capital, and volatility.
Open Thermo Fisher and Agilent both use service ecosystems, but capital allocation decides which model compounds better.
Open AI chips still need to be tested, and Teradyne sits in that less flashy bottleneck.
Open Palantir's index-inclusion narrative can attract attention, but institutional flow only matters if business fundamentals keep confirming the story.
Open Palantir is a profitable AI software company, but government contract quality matters more than headlines.
Open Planet posted record revenue and a much bigger cash position, but retail investors still have to decide whether backlog can turn into cleaner profits.
Open Pfizer reported FY2025 revenue of $62.6 billion and Q1 2026 revenue of $14.5 billion. The thesis depends on portfolio durability, oncology integration, patent cliffs, operating cash flow, debt capacity and pipeline execution.
Open Joby needs certification progress to arrive before liquidity concerns dominate the air-taxi story.
Open Joby has an ambitious air-taxi network vision, but the financial runway comes before scale.
Open